Literature DB >> 993353

Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man.

J S Flier, C R Kahn, D B Jarrett, J Roth.   

Abstract

We have characterized the circulating inhibitor of insulin receptor binding found in several patients with a new syndrome of extreme insulin resistance. The inhibitor is an immunoglobulin by multiple criteria, including precipitation by 33% ammonium sulfate, migration on G-200 Sephadex gel filtration and DEAE chromatography, and immuno-precipitation with specific anti-human immuno-globulins. Although predominantly IgG, some activity is found in the IgM fraction of the immunoglobulins in one patient. The inhibitory immunoglobulins reacted with antisera to both kappa and lambda light chain determinants and are therefore polyclonal. In addition, activity is retained in the F(ab')2 fraction of pepsin-digested IgG. Evidence suggests that these antibodies are directed at determinants on or near the insulin receptor, and that they are responsible for the observed clinical insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 993353      PMCID: PMC333316          DOI: 10.1172/JCI108600

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  24 in total

1.  INSULIN RESISTANCE AND ACANTHOSIS NIGRICANS.

Authors:  W R TUCKER; D KLINK; F GOETZ; E ZALME; H C KNOWLES
Journal:  Diabetes       Date:  1964 Jul-Aug       Impact factor: 9.461

2.  The bioassay of thyrotropin in serum.

Authors:  J M McKENZIE
Journal:  Endocrinology       Date:  1958-09       Impact factor: 4.736

3.  Demonstration that monocytes rather than lymphocytes are the insulin-binding cells in preparations of humah peripheral blood mononuclear leukocytes: implications for studies of insulin-resistant states in man.

Authors:  R H Schwartz; A R Bianco; B S Handwerger; C R Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

4.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

5.  Thyroid-stimulating immunoglobulins in Graves' disease.

Authors:  B R Smith; R Hall
Journal:  Lancet       Date:  1974-08-24       Impact factor: 79.321

6.  Effects of long-acting thyroid stimulator on thyrotropin stimulation of adenyl cyclase activity in thyroid plasma membranes.

Authors:  K Yamashita; J B Field
Journal:  J Clin Invest       Date:  1972-03       Impact factor: 14.808

7.  Immunopharmacological disease: a break in tolerance to receptor sites.

Authors:  V A Lennon; P R Carnegie
Journal:  Lancet       Date:  1971-03-27       Impact factor: 79.321

8.  Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance.

Authors:  J S Flier; C R Kahn; J Roth; R S Bar
Journal:  Science       Date:  1975-10-03       Impact factor: 47.728

9.  The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man.

Authors:  C R Kahn; J S Flier; R S Bar; J A Archer; P Gorden; M M Martin; J Roth
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

10.  Insulin-resistant diabetes associated with increased endogenous plasma insulin followed by complete remission.

Authors:  J B FIELD; P JOHNSON; B HERRING
Journal:  J Clin Invest       Date:  1961-09       Impact factor: 14.808

View more
  45 in total

Review 1.  Antibodies directed to the insulin receptor. Clinical aspects and applications to the study of insulin action.

Authors:  R De Pirro; P Borboni; M A Marini; A Montemurro; G Sesti; R Lauro
Journal:  J Endocrinol Invest       Date:  1990-12       Impact factor: 4.256

2.  Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen.

Authors:  C Bruck; M S Co; M Slaoui; G N Gaulton; T Smith; B N Fields; J I Mullins; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

3.  Effects of autoantibodies to the insulin receptor on isolated adipocytes. Studies of insulin binding and insulin action.

Authors:  C R Kahn; K Baird; J S Filier; D B Jarrett
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

4.  Systemic lupus erythematosus presenting as hypoglycemia with insulin receptor antibodies.

Authors:  R L Howard; L K Beck; A Schneebaum
Journal:  West J Med       Date:  1989-09

5.  Insulin stimulates phosphorylation of a 120-kDa glycoprotein substrate (pp120) for the receptor-associated protein kinase in intact H-35 hepatoma cells.

Authors:  N Perrotti; D Accili; B Marcus-Samuels; R W Rees-Jones; S I Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies.

Authors:  R Malek; A Y Chong; B C Lupsa; A O Lungu; E K Cochran; M A Soos; R K Semple; J E Balow; P Gorden
Journal:  J Clin Endocrinol Metab       Date:  2010-05-19       Impact factor: 5.958

7.  Direct demonstration that receptor crosslinking or aggregation is important in insulin action.

Authors:  C R Kahn; K L Baird; D B Jarrett; J S Flier
Journal:  Proc Natl Acad Sci U S A       Date:  1978-09       Impact factor: 11.205

Review 8.  Polyglandular autoimmune syndrome: current concepts.

Authors:  J Meyerson; E E Lechuga-Gomez; P E Bigazzi; P G Walfish
Journal:  CMAJ       Date:  1988-04-01       Impact factor: 8.262

9.  Immunoprecipitation of 125I-insulin crosslinked receptor.

Authors:  T Tsushima; Y Ohmori; H Murakami; K Shizume; Y Hirata
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

10.  Clinical evaluation of insulin resistance and beta-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus.

Authors:  Tim K Tso; Hui-Yu Huang; Chen-Kang Chang; Ying-Ju Liao; Wen-Nan Huang
Journal:  Clin Rheumatol       Date:  2004-05-18       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.